Cluster 2 (blue) includes 14 items on the application of immunotherapy to cancer, including atezolizumab, immune checkpoint inhibitors, nivolumab, PD-1&PD-L1, clinical outcome, and resistance. The gene discussed is CD274; the disease is cancer.